ID
45367
Beschrijving
Principal Investigator: Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA MeSH: Pancreatic Neoplasms,Carcinoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000550 In this study, we whole genome sequenced tumor/normal pairs from three pancreatic adenocarcinoma patients to separately characterize each patient with respect to somatic alterations. For 2 patients for whom tumor RNA was available, we also performed RNA sequencing to evaluate gene expression changes. While additional sequencing is needed to improve our understanding of the disease, the information acquired from this study contributes to our knowledge base on pancreatic cancer and helps to establish a foundation for identifying and developing more efficacious treatments for patients.
Link
Trefwoorden
Versies (1)
- 04-11-22 04-11-22 - Chiara Middel
Houder van rechten
Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA
Geüploaded op
4 november 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000550 Characterization of Pancreatic Adenocarcinoma Patients Using NGS
Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, type of research were used, and consent group of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, age, sex, race, and current status of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage of samples, and type of tumor treatment for samples obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
Similar models
Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, type of research were used, and consent group of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, age, sex, race, and current status of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage of samples, and type of tumor treatment for samples obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.